Fig. 8From: Construction of a risk model and prediction of prognosis and immunotherapy based on cuproptosis-related LncRNAs in the urinary system pan-cancerDrug sensitivity analysis in low- and high-risk groups. A Belinostat, B docetaxel, C tipifarnib, D tubastatin, E YM201636A, F Cisplatin, G bortezomib, H axitinib, I bosutinib, J camptothecinBack to article page